|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:budesonide
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
Entocort EC
|
|
gptkbp:class
|
gptkb:physicist
|
|
gptkbp:clinical_trial
|
Phase III
maintenance therapy
induction therapy
|
|
gptkbp:contraindication
|
active infections
hypersensitivity to budesonide
|
|
gptkbp:dosage_form
|
3 mg
|
|
gptkbp:duration
|
up to 8 weeks
|
|
gptkbp:education
|
do not stop abruptly
report any unusual symptoms
follow up with healthcare provider
|
|
gptkbp:effective_date
|
gptkb:1997
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:first_released
|
gptkb:battle
|
|
gptkbp:formulation
|
gptkb:beer
extended-release
|
|
gptkbp:has_ability
|
3 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Entocort
|
|
gptkbp:indication
|
gptkb:Crohn's_disease
gptkb:ulcerative_colitis
|
|
gptkbp:ingredients
|
gptkb:budesonide
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_atype_of
|
A07 E A06
|
|
gptkbp:is_monitored_by
|
adrenal function
growth in children
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:legal_issue
|
prescription only
|
|
gptkbp:lifespan
|
3 to 5 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:temple
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:pharmacokinetics
|
anti-inflammatory effects
high first-pass metabolism
|
|
gptkbp:population
|
take with food
do not crush or chew
swallow whole
|
|
gptkbp:safety_features
|
Category B
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
abdominal pain
weight gain
infection risk
mood changes
hyperglycemia
osteoporosis risk
|
|
gptkbp:social_structure
|
C25 H34 O6
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for efficacy
|